Cargando…
Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma
Autores principales: | Dennis, Lucas, Fling, Steven P, Beechem, Joseph M, Danaher, Patrick, D'Amico, Leonard, Disis, Mary, Elliott, Nathan, Geller, Melissa, Jacquemont, Celine, Kussick, Steven, Shine, Richard, Odunsi, Kunle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646049/ http://dx.doi.org/10.1186/2051-1426-3-S2-P84 |
Ejemplares similares
-
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
por: Morishima, Chihiro, et al.
Publicado: (2015) -
CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014) -
Gene expression markers of Tumor Infiltrating Leukocytes
por: Danaher, Patrick, et al.
Publicado: (2017) -
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
por: Morishima, Chihiro, et al.
Publicado: (2014) -
nCounter(®) PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
por: Cesano, Alessandra
Publicado: (2015)